- From: Sleepalot <sleepalot07@xxxxxxxxxxx>
- Date: Sat, 11 Dec 2010 16:45:36 +0000
JPinNY <jpinny@xxxxxxxxxxx> wrote:
On 12/09/2010 12:58 AM, Sleepalot wrote:
"a l l y"<ally@xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx> wrote:You may certainly equivocate,
Well, I just heard about this on Radio 4 this morning, so I now know what
Edith was talking about:
Ah, thanks for that.
The major finding of the study is that more research is needed.
(The most common finding. ;-)
From the Lancet:
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an
international consensus statement
Evidence clearly shows a chemopreventive effect for aspirin and other
non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably
other cancer types;
however, data on the risk?benefit profile for cancer prevention are insufficient
and no definitive recommendations can be made.
Aspirin has emerged as the most likely NSAID for use in chemoprevention because
of its known cardiovascular benefit and available safety and efficacy data.
Other traditional NSAIDs, particularly sulindac, and selective COX-2 inhibitors
are now given to patients at high risk of colorectal cancer, although these
drugs do not provide cardioprotection. More studies of aspirin and cancer
prevention are needed to define the lowest effective dose, the age at which to
initiate therapy, the optimum treatment duration, and the subpopulations for
which the benefits of chemoprevention outweigh the risks of adverse
side-effects. Although it might be possible to answer some of these questions
with longer follow-up of existing clinical trials, randomised controlled trials
with new study designs will be needed. Future projects should investigate the
effects of aspirin treatment on multiple organ systems. Cancers of interest are
colorectal, breast, prostate, lung, stomach, and oesophageal. The main
side-effect of aspirin is peptic ulcers; therefore coadministration of aspirin
with a proton-pump inhibitor is an attractive option and is under investigation
in the AspECT trial.
Huh? How am I misleading?
but this is a very promising ray of hope
in the battle to prevent cancer. The research professor, Peter
Rothwell,says the research 'tips things towards it (aspirin-based
chemoprevention) being worth it'. Sounds good to me.
Hmmm. I'm inclined to think the study has problems, partly because the
25,000 subjects weren't healthy people, (one sure way of not getting
cancer is to die of something else) and so, not necessarily representative
of the general population. Also, the (8? original) studies done weren't intended
to test the cancer-protection hypothesis, so it'll be sub-optimal data with all
sorts of confounding factors.
- Prev by Date: 9-12-2010
- Next by Date: Re: BBC FOUR: Folk at the BBC.
- Previous by thread: Re: aspirin
- Next by thread: Mistletoe